Table 3.
Prevalence of hepatitis B virus infection markers among children born in 2006–2015 by age group and sex across survey sites — Ukraine, 2017
| Variable | Total No. tested | Anti-HBc-positive | HBsAg-positive | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. positive | Weighted % |
95% CI | P value | No. positive | Weighted % |
95% CI | P value | ||
| Zakarpattya | |||||||||
| Overall | 1,268 | 56 | 5.2 | 3.1–8.7 | 6 | 0.7 | 0.3–1.4 | ||
| Age groups | |||||||||
| 2006 –2009 cohorts | 667 | 21 | 3.3 | 2.1–5.2 | 0.092 | 1 | 0.1 | 0.0 –0.8 | 0.045 |
| 2010 –2015 cohorts | 601 | 35 | 6.4 | 3.4–1.5 | 5 | 1.0 | 0.4–2.2 | ||
| Sex | |||||||||
| Male | 675 | 26 | 4.5 | 2.6–7.8 | 0.280 | 2 | 0.5 | 0.1–1.7 | 0.450 |
| Female | 593 | 30 | 5.9 | 3.3–10.4 | 4 | 0.9 | 0.3–2.2 | ||
| Sumy | |||||||||
| Overall | 1,380 | 12 | 0.8 | 0.4–1.6 | 1 | 0.1 | 0.0–0.4 | ||
| Age groups | |||||||||
| 2006 –2009 cohorts | 699 | 8 | 1.1 | 0.4–2.7 | 0.423 | 1 | 0.1 | 0.0–0.8 | n/a |
| 2010 –2015 cohorts | 681 | 4 | 0.6 | 0.2–1.8 | 0 | 0.0 | 0.0–0.6* | ||
| Sex | |||||||||
| Male | 719 | 5 | 0.6 | 0.2–1.6 | 0.332 | 0 | 0.0 | 0.0–0.5* | n/a |
| Female | 661 | 7 | 0.9 | 0.4–2.0 | 1 | 0.1 | 0.0–0.8 | ||
| Odessa | |||||||||
| Overall | 1,265 | 14 | 1.0 | 0.4–2.2 | 0 | 0.0 | 0.0–0.3* | ||
| Age groups | |||||||||
| 2006 –2009 cohorts | 663 | 11 | 1.6 | 0.8–3.1 | 0.033 | 0 | 0.0 | n/a | |
| 2010 –2015 cohorts | 602 | 3 | 0.5 | 0.1–2.2 | 0 | 0.0 | |||
| Sex | |||||||||
| Male | 654 | 6 | 0.9 | 0.3–2.6 | 0.669 | 0 | 0.0 | n/a | |
| Female | 611 | 8 | 1.1 | 0.5–2.3 | 0 | 0.0 | |||
| Kyiv City | |||||||||
| Overall | 683 | 7 | 1.1 | 0.5–2.3 | 2 | 0.1 | 0.0–0.8 | ||
| Age groups | |||||||||
| 2006 –2009 cohorts | 352 | 3 | 0.8 | 0.3–2.5 | 0.640 | 1 | 0.3 | 0.1–1.6 | n/a |
| 2010 –2015 cohorts | 331 | 4 | 1.2 | 0.5–3.1 | 0 | 0.0 | 0.0–1.2* | ||
| Sex | |||||||||
| Male | 343 | 3 | 1.0 | 0.3–2.9 | 0.800 | 0 | 0.0 | 0.0–1.1* | n/a |
| Female | 340 | 4 | 1.2 | 0.4–3.1 | 1 | 0.2 | 0.0–1.5 | ||
Note: CI, confidence interval; n/a, not applicable (could not be calculated because of zero prevalence); anti-HBc, antibodies against core antigen of hepatitis B virus; HBsAg, surface antigen of hepatitis B virus.
Crude estimate of CI (due to zero value of prevalence)